Cargando…

Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition

A large proportion of colorectal carcinomas (CRC) evolve from colorectal adenomas. However, not all individuals with colonic adenomas have a risk of CRC substantially higher than those of the general population. The aim of the study was to determine the differences or similarities of mutation profil...

Descripción completa

Detalles Bibliográficos
Autores principales: Jungwirth, Jiri, Urbanova, Marketa, Boot, Arnoud, Hosek, Petr, Bendova, Petra, Siskova, Anna, Svec, Jiri, Kment, Milan, Tumova, Daniela, Summerova, Sandra, Benes, Zdenek, Buchler, Tomas, Kohout, Pavel, Hucl, Tomas, Matej, Radoslav, Vodickova, Ludmila, van Wezel, Tom, Vodicka, Pavel, Vymetalkova, Veronika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850440/
https://www.ncbi.nlm.nih.gov/pubmed/35173208
http://dx.doi.org/10.1038/s41598-022-06498-9
_version_ 1784652599092314112
author Jungwirth, Jiri
Urbanova, Marketa
Boot, Arnoud
Hosek, Petr
Bendova, Petra
Siskova, Anna
Svec, Jiri
Kment, Milan
Tumova, Daniela
Summerova, Sandra
Benes, Zdenek
Buchler, Tomas
Kohout, Pavel
Hucl, Tomas
Matej, Radoslav
Vodickova, Ludmila
van Wezel, Tom
Vodicka, Pavel
Vymetalkova, Veronika
author_facet Jungwirth, Jiri
Urbanova, Marketa
Boot, Arnoud
Hosek, Petr
Bendova, Petra
Siskova, Anna
Svec, Jiri
Kment, Milan
Tumova, Daniela
Summerova, Sandra
Benes, Zdenek
Buchler, Tomas
Kohout, Pavel
Hucl, Tomas
Matej, Radoslav
Vodickova, Ludmila
van Wezel, Tom
Vodicka, Pavel
Vymetalkova, Veronika
author_sort Jungwirth, Jiri
collection PubMed
description A large proportion of colorectal carcinomas (CRC) evolve from colorectal adenomas. However, not all individuals with colonic adenomas have a risk of CRC substantially higher than those of the general population. The aim of the study was to determine the differences or similarities of mutation profile among low- and high-grade adenomas and in situ carcinoma with detailed follow up. We have investigated the mutation spectrum of well-known genes involved in CRC (such as APC, BRAF, EGFR, NRAS, KRAS, PIK3CA, POLE, POLD1, SMAD4, PTEN, and TP53) in a large, well-defined series of 96 adenomas and in situ carcinomas using a high-throughput genotyping technique. Besides, the microsatellite instability and APC and MLH1 promoter methylation were studied as well. We observed a high frequency of pathogenic variants in the studied genes. The APC, KRAS and TP53 mutation frequencies were slightly lower in adenoma samples than in in situ carcinoma samples. Further, when we stratified mutation frequency based on the grade, the frequency distribution was as follows: low-grade adenoma—high-grade adenomas—in situ carcinoma: APC gene 42.9–56.0–54.5%; KRAS gene 32.7–32.0–45.5%; TP53 gene 8.2–20.0–18.2%. The occurrence of KRAS mutation was associated with the presence of villous histology and methylation of the APC promoter was significantly associated with the presence of POLE genetic variations. However, no association was noticed with the presence of any singular mutation and occurrence of subsequent adenoma or CRC. Our data supports the multistep model of gradual accumulation of mutations, especially in the driver genes, such as APC, TP53 and KRAS.
format Online
Article
Text
id pubmed-8850440
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-88504402022-02-17 Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition Jungwirth, Jiri Urbanova, Marketa Boot, Arnoud Hosek, Petr Bendova, Petra Siskova, Anna Svec, Jiri Kment, Milan Tumova, Daniela Summerova, Sandra Benes, Zdenek Buchler, Tomas Kohout, Pavel Hucl, Tomas Matej, Radoslav Vodickova, Ludmila van Wezel, Tom Vodicka, Pavel Vymetalkova, Veronika Sci Rep Article A large proportion of colorectal carcinomas (CRC) evolve from colorectal adenomas. However, not all individuals with colonic adenomas have a risk of CRC substantially higher than those of the general population. The aim of the study was to determine the differences or similarities of mutation profile among low- and high-grade adenomas and in situ carcinoma with detailed follow up. We have investigated the mutation spectrum of well-known genes involved in CRC (such as APC, BRAF, EGFR, NRAS, KRAS, PIK3CA, POLE, POLD1, SMAD4, PTEN, and TP53) in a large, well-defined series of 96 adenomas and in situ carcinomas using a high-throughput genotyping technique. Besides, the microsatellite instability and APC and MLH1 promoter methylation were studied as well. We observed a high frequency of pathogenic variants in the studied genes. The APC, KRAS and TP53 mutation frequencies were slightly lower in adenoma samples than in in situ carcinoma samples. Further, when we stratified mutation frequency based on the grade, the frequency distribution was as follows: low-grade adenoma—high-grade adenomas—in situ carcinoma: APC gene 42.9–56.0–54.5%; KRAS gene 32.7–32.0–45.5%; TP53 gene 8.2–20.0–18.2%. The occurrence of KRAS mutation was associated with the presence of villous histology and methylation of the APC promoter was significantly associated with the presence of POLE genetic variations. However, no association was noticed with the presence of any singular mutation and occurrence of subsequent adenoma or CRC. Our data supports the multistep model of gradual accumulation of mutations, especially in the driver genes, such as APC, TP53 and KRAS. Nature Publishing Group UK 2022-02-16 /pmc/articles/PMC8850440/ /pubmed/35173208 http://dx.doi.org/10.1038/s41598-022-06498-9 Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Jungwirth, Jiri
Urbanova, Marketa
Boot, Arnoud
Hosek, Petr
Bendova, Petra
Siskova, Anna
Svec, Jiri
Kment, Milan
Tumova, Daniela
Summerova, Sandra
Benes, Zdenek
Buchler, Tomas
Kohout, Pavel
Hucl, Tomas
Matej, Radoslav
Vodickova, Ludmila
van Wezel, Tom
Vodicka, Pavel
Vymetalkova, Veronika
Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition
title Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition
title_full Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition
title_fullStr Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition
title_full_unstemmed Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition
title_short Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition
title_sort mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850440/
https://www.ncbi.nlm.nih.gov/pubmed/35173208
http://dx.doi.org/10.1038/s41598-022-06498-9
work_keys_str_mv AT jungwirthjiri mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition
AT urbanovamarketa mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition
AT bootarnoud mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition
AT hosekpetr mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition
AT bendovapetra mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition
AT siskovaanna mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition
AT svecjiri mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition
AT kmentmilan mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition
AT tumovadaniela mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition
AT summerovasandra mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition
AT beneszdenek mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition
AT buchlertomas mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition
AT kohoutpavel mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition
AT hucltomas mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition
AT matejradoslav mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition
AT vodickovaludmila mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition
AT vanwezeltom mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition
AT vodickapavel mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition
AT vymetalkovaveronika mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition